SNAP-8 (Acetyl Octapeptide-3)

Research-Grade

SNAP-8 (Acetyl Octapeptide-3) is an elongated version of Argireline (Acetyl Hexapeptide-3) with two additional amino acids. Both peptides were developed by Lipotec (now part of Lubrizol/Ashland) as topical alternatives to botulinum toxin injections for expression wrinkle reduction. The mechanism is conceptually elegant: SNAP-25 is one of three SNARE complex proteins required for acetylcholine vesicle fusion at the neuromuscular junction. By competing with native SNAP-25, SNAP-8 partially inhibits this fusion, reducing muscle contraction intensity. This is the same pathway that botulinum toxin targets — but at a different step and with far lower potency. Clinical data from Lipotec shows wrinkle depth reduction of up to 63% after 28 days at 10% concentration in a cream base, measured by skin profilometry. Independent replication of these figures is limited, and real-world results are more modest. The key limitation is penetration: topical peptides must cross the stratum corneum to reach dermal nerve endings, and delivery efficiency is low without specialized vehicles. SNAP-8 is widely formulated in anti-wrinkle serums and creams, often alongside Argireline, Matrixyl, and other signal peptides. It is considered well-tolerated with no significant adverse effects reported in clinical or post-market data.